Observational studyBMC anesthesiology2025
Exploring vasopressin use in septic shock: a retrospective cohort study from Türkiye (VASCO-TURK).
Observational study in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06953297 (Exploring Vasopressin Use in Septic Shock), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exploring Vasopressin Use in Septic Shock: A Retrospective Cohort Study From Türkiye
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVasopressin is a peptide hormone and often added to reduce catecholamine dose and side effects according to recent guidelines. Despite increasing global interest in vasopressin use in septic shock, real-world data from low- to middle-income countries, including Türkiye, remain scarce. MATERIAL-
methodThis study was conducted as a single-center, retrospective, observational study in a tertiary intensive care unit, with the diagnosis of septic shock according to Surviving Sepsis Campaign guidelines and who received norepinephrine alone and both norepinephrine with vasopressin as an adjunctive vasopressor.
resultsA total of 146 septic shock patients were included in the study, with 113 (77.4%) in the norepinephrine group and 33 (22.6%) in the patients receiving adjunctive vasopressin therapy. Overall survival: 24.2% in adjunctive vasopressin group vs. 24.8% in norepinephrine group (p = 1.000). Median norepinephrine dose decreased significantly from 0.55 mcg/kg/min (IQR: 0.44-0.84) at baseline to 0.43 mcg/kg/min (IQR: 0.27-0.72) by the 6th hour (p = 0.010), supporting a vasopressor-sparing effect of vasopressin. Adjunctive vasopressin initiation time was 14 h (IQR 5-25 h), and the initial norepinephrine dose at the time of vasopressin introduction was, 0.56 mcg/kg/min (IQR 0.445-0.880). Mean arterial pressure (MAP), improved from 60 mmHg (IQR: 54-66) at hour 0 to 70 mmHg (IQR: 63.08-75.75) at hour 2 and 74 mmHg (IQR: 61.75-83.5) at hour 6 (p < 0.001). Heart rate initially remained stable between baseline and the 2nd hour (110 vs. 110 bpm), but decreased significantly by the 6th hour to a median of 97.5 bpm (IQR: 88.75-120.5; p = 0.003).
conclusionThis single center study, with a limited number of patients, is valuable as it reflects the first national experience with vasopressin. In this study, no difference in mortality was observed between patients receiving norepinephrine alone and those receiving vasopressin in combination with norepinephrine. Vasopressin demonstrated a significant norepinephrine-sparing effect, improved heart rate control, and increased mean arterial pressure, suggesting potential hemodynamic stabilization.
trial registrationThe study is registered at ClinicalTrials.gov (NCT06953297). Public release date: April 23, 2025.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.